Clinical Evaluation of an HTK Solution for Liver Transplantation: A Phase 3 Randomized Pilot Clinical Trial Study.
Clinical trial
HTK
Organ transplantation
Preservation solution
Prognosis
Transplantation
Journal
Archives of Iranian medicine
ISSN: 1735-3947
Titre abrégé: Arch Iran Med
Pays: Iran
ID NLM: 100889644
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
17
07
2021
accepted:
27
02
2022
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
6
8
2023
Statut:
epublish
Résumé
Organ preservation solutions are not easily accessible in Iran, similar to many resource-limited countries. We aimed to evaluate the efficacy of a locally-produced HTK solution among adult liver transplantation candidates in a pilot clinical trial study. Adult patients undergoing liver transplantation were randomly allocated into two groups. One received the HTK solution (PharMedCina Inc., Shiraz, Iran), and the second received the commercially available HTK solution (Custodiol Overall, 28 individuals entered the study, including 11 and 9 males (78.6% and 64.3%) in the Custodiol Based on the findings of this pilot study with the current sample size, no statistically significant difference was found between our locally-produced HTK solution and Custodiol
Sections du résumé
BACKGROUND
Organ preservation solutions are not easily accessible in Iran, similar to many resource-limited countries. We aimed to evaluate the efficacy of a locally-produced HTK solution among adult liver transplantation candidates in a pilot clinical trial study.
METHODS
Adult patients undergoing liver transplantation were randomly allocated into two groups. One received the HTK solution (PharMedCina Inc., Shiraz, Iran), and the second received the commercially available HTK solution (Custodiol
RESULTS
Overall, 28 individuals entered the study, including 11 and 9 males (78.6% and 64.3%) in the Custodiol
CONCLUSION
Based on the findings of this pilot study with the current sample size, no statistically significant difference was found between our locally-produced HTK solution and Custodiol
Identifiants
pubmed: 37543887
doi: 10.34172/aim.2022.97
doi:
Substances chimiques
Bretschneider cardioplegic solution
0
Organ Preservation Solutions
0
Glucose
IY9XDZ35W2
Glutathione
GAN16C9B8O
Insulin
0
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-623Informations de copyright
© 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.